Company profile: Oxford Cancer Biomarkers
1.1 - Company Overview
Company description
- Provider of colorectal cancer biomarker tests, developing and commercializing a suite of diagnostics to improve the current treatment pathway; closely affiliated with the Institute of Cancer Medicine at Oxford University, where its founders lead translational cancer science research.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Oxford Cancer Biomarkers
X4 Pharmaceuticals
HQ: United States
Website
- Description: Provider of oral small molecule CXCR4 antagonists, including mavorixafor to mobilize white blood cells and improve immune function in patients with WHIM syndrome and certain chronic neutropenic disorders; runs a global Phase 3 WHIM trial with positive results and awaiting FDA approval, plus a Phase 2 trial in chronic neutropenic disorders with plans for Phase 3.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full X4 Pharmaceuticals company profile →
Imagion Biosystems
HQ: United States
Website
- Description: Provider of molecularly targeted magnetic nanoparticles (MagSense) for cancer detection, developing imaging agents for solid tumors to aid diagnosis and staging, and conducting a Phase 1 HER2 breast cancer lymph node study aiming to avoid biopsies. Offers PrecisionMRX nanoparticles for MRI, hyperthermia, and magnetic particle imaging; supplies SPIONs with multiple coatings and nanoparticles for third-party biomedical applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imagion Biosystems company profile →
Antigen Express
HQ: United States
Website
- Description: Provider of proprietary vaccine formulation platform and products addressing large unmet medical needs by focusing on stimulation of critical T helper cells. The technology enables antigen-specific stimulation or suppression of T-helper responses to virtually any antigen.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Antigen Express company profile →
Bolt Biotherapeutics
HQ: United States
Website
- Description: Provider of a biotechnology platform for cancer immunotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bolt Biotherapeutics company profile →
Pheon Therapeutics
HQ: United Kingdom
Website
- Description: Provider of antibody-drug conjugate (ADC) programs for difficult-to-treat cancers. Offerings include PHN-010, an ADC targeting a transmembrane protein over-expressed in multiple solid tumors with low expression in healthy tissues; development of first-in-class solid tumor programs with in vivo proof of concept; and proprietary payloads to overcome resistance, featuring novel modes of action and tunable potency.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pheon Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Oxford Cancer Biomarkers
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Oxford Cancer Biomarkers
2.2 - Growth funds investing in similar companies to Oxford Cancer Biomarkers
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Oxford Cancer Biomarkers
4.2 - Public trading comparable groups for Oxford Cancer Biomarkers
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →